blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3807401

EP3807401 - LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  19.03.2021
Database last updated on 03.09.2024
FormerThe international publication has been made
Status updated on  21.12.2019
Formerunknown
Status updated on  03.07.2019
Most recent event   Tooltip24.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Universität Bern
Hochschulstrasse 6
3012 Bern / CH
[2021/16]
Inventor(s)01 / OCHSENBEIN, Adrian
Breitenrain 28
3032 Hinterkappelen / CH
02 / HÖPPNER, Sabine
Fabrikstrasse 20B
3012 Bern / CH
03 / RIETHER, Carsten
Gesellschaftsstrasse 44
3012 Bern / CH
 [2021/16]
Representative(s)Schulz Junghans Patentanwälte PartGmbB
Großbeerenstraße 71
10963 Berlin / DE
[2021/16]
Application number, filing date19732936.014.06.2019
[2021/16]
WO2019EP65780
Priority number, dateEP2018017805015.06.2018         Original published format: EP 18178050
[2021/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019238966
Date:19.12.2019
Language:EN
[2019/51]
Type: A1 Application with search report 
No.:EP3807401
Date:21.04.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 19.12.2019 takes the place of the publication of the European patent application.
[2021/16]
Search report(s)International search report - published on:EP19.12.2019
ClassificationIPC:C12N5/0789, A61K48/00, A61K39/00
[2021/16]
CPC:
C12N5/0647 (EP); C07K16/2875 (US); A61P35/02 (EP,US);
C12N15/86 (US); A01K2207/12 (EP); A01K2217/075 (EP);
A01K2227/105 (EP); C12N2501/25 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/16]
TitleGerman:LIGANDEN GEGEN LIGHT ODER DESSEN REZEPTOR LTSSR ZUR VERWENDUNG BEI HÄMATOLOGISCHEN MALIGNOMEN[2021/16]
English:LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES[2021/16]
French:LIGANDS DE LIGHT OU DE SON RÉCEPTEUR LTßR DESTINÉS À ÊTRE UTILISÉS DANS DES MALIGNITÉS HÉMATOLOGIQUES[2021/16]
Entry into regional phase07.12.2020National basic fee paid 
07.12.2020Designation fee(s) paid 
07.12.2020Examination fee paid 
Examination procedure07.12.2020Examination requested  [2021/16]
07.12.2020Date on which the examining division has become responsible
29.07.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
23.06.2021Renewal fee patent year 03
31.03.2022Renewal fee patent year 04
29.06.2023Renewal fee patent year 05
24.06.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XAY]US2011171242  (WARE CARL [US]) [X] 1-3,5,11 * paragraph [0029] * * paragraph [0128] - paragraph [0130] * [A] 6-10 [Y] 4;
 [IY]WO2004031409  (ONCOTHERAPY SCIENCE INC [JP], et al) [I] 1-11 * page 41; table 3 * * claims 1, 18, 23-25 * * page 24, paragraph 2 * [Y] 1-11;
 [Y]US2006134102  (LEPAGE DOREEN [US], et al) [Y] 1-11 * paragraph [0056] * * paragraph [0119] * * page 23; example 3 *;
 [A]EP0954333  (BIOGEN INC [US]) [A] 1-11 * the whole document *;
 [A]WO2010046289  (UNIV ZUERICH PROREKTORAT MNW [CH], et al) [A] 1-11 * page 4 - page 7; claims 1-15 *;
 [A]EP2157981  (INST NAT SANTE RECH MED [FR], et al) [A] 1-11 * the whole document *;
 [A]WO9902563  (JOLLA INST ALLERGY IMMUNOLOG [US]) [A] 1-11 * the whole document *;
 [A]WO9817313  (BIOGEN INC [US], et al) [A] 1-11 * the whole document *
 [A]  - ZHAI Y ET AL, "LIGHT, A NOVEL LIGAND FOR LYMPHOTOXIN BETA RECEPTOR AND TR2/HVEM INDUCES APOPTOSIS AND SUPPRESSES IN VIVO TUMOR FORMATION VIA GENE TRANSFER", JOURNAL OF CLINICAL INVESTIGATION,, (19980901), vol. 102, no. 6, doi:10.1172/JCI3492, ISSN 0021-9738, pages 1142 - 1151, XP002947576 [A] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.1172/JCI3492
by applicantUS2012142611
 US2016250341
 US2016075767
 US2015368302
 US2011165621
    - SCHUETTPELZ, L.G.LINK, D.C. et al., Frontiers in immunology, (20130000), vol. 4
    - VINCKE et al., "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold", J Biol Chem., (20090130), vol. 284, no. 5, doi:doi:10.1074/jbc.M806889200, pages 3273 - 3284, XP009124408

DOI:   http://dx.doi.org/10.1074/jbc.M806889200
    - FUTTERER, A.MINK, K.LUZ, A.KOSCO-VILBOIS, M.H.PFEFFER, K., Immunity, (19980000), vol. 9, pages 59 - 70
    - MUMPRECHT, S.SCHURCH, C.SCHWALLER, J.SOLENTHALER, M.OCHSENBEIN, A.F., Blood, (20090000), vol. 114, pages 5191 - 5200
    - SCHEPERS, K. et al., Cell stem cell, (20130000), vol. 13, pages 285 - 299
    - SCHEPERS, K.HSIAO, E.C.GARG, T.SCOTT, M.J.PASSEGUE, E., Blood, (20120000), vol. 120, pages 3425 - 3435
    - WILSON, A. et al., Annals of the New York Academy of Sciences, (20070000), vol. 1106, pages 64 - 75
    - SCHURCH, C.RIETHER, C.MATTER, M.S.TZANKOV, A.OCHSENBEIN, A.F., The Journal of clinical investigation, (20120000), vol. 122, pages 624 - 638
    - RIETHER, C. et al., The Journal of experimental medicine, (20170000), vol. 214, pages 359 - 380
    - RADPOUR, R. et al., PloS one, (20110000), vol. 6, page e27355
    - WONG, C.C. et al., Nature biotechnology, (20100000), vol. 28, pages 1115 - 1121
    - UNTERGASSER, A. et al., Nucleic acids research, (20070000), vol. 35, pages W71 - 74
    - LIVAK, K.J.SCHMITTGEN, T.D., Methods, (20010000), vol. 25, pages 402 - 408
    - PANG, W.W. et al., Proceedings of the National Academy of Sciences of the United States of America, (20110000), vol. 108, no. 50, pages 20012 - 20017
    - REBEL, V.I. et al., Journal of Experimental Medicine, (19990000), vol. 190, no. 10, pages 1493 - 504
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.